The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting

Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting

Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649

Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21

Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504

Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States

Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495

The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism

Koo, S., Flechner, L., Qi, L., Zhang, X., Screaton, R. A., Jeffries, S., Hedrick, S. A., Xu, W., Boussouar, F., Brindle, P. K., et al. (2005) · Nature · doi:10.1038/nature03967 · Cited by 1,026

Sorting out the roles of PPAR in energy metabolism and vascular homeostasis

Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962

Glucagon and regulation of glucose metabolism

Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905

Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice

Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563

ADD1/SREBP-1c Is Required in the Activation of Hepatic Lipogenic Gene Expression by Glucose

Foretz, M., Pacot, C., Dugail, I., Lemarchand, P., Guichard, C., Lièpvre, X. L., Lubrano-Berthelier, C., Spiegelman, B. M., Kim, J. B., Ferré, P., et al. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3760 · Cited by 548

International Union of Pharmacology. XXXV. The Glucagon Receptor Family

Mayo, K. E., Miller, L. J., BATAILLE, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 514

Expression cloning and signaling properties of the rat glucagon receptor

Jelinek, L., Lok, S., Rosenberg, G., Smith, R., Grant, F., BIGGS, S., Bensch, P., Kuijper, J. L., Sheppard, P. O., Sprecher, C. A., et al. (1993) · Science · doi:10.1126/science.8384375 · Cited by 397

Energy Metabolism in the Liver

Rui, L. (2014) · Comprehensive physiology · doi:10.1002/cphy.c130024 · Cited by 2,401

Regulation of hepatic glucose metabolism in health and disease

Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.80 · Cited by 1,159

Metabolism disrupting chemicals and metabolic disorders

Heindel, J. J., Blumberg, B., Cave, M., Machtinger, R., Mantovani, A., Mendez, M. A., Nadal, A., Palanza, P., Panzica, G., Sargis, R., et al. (2017) · Reproductive Toxicology · doi:10.1016/j.reprotox.2016.10.001 · Cited by 1,101

Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease

Kawano, Y., & Cohen, D. E. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0758-5 · Cited by 1,009

FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response

Potthoff, M. J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B. N., Mangelsdorf, D. J., Kliewer, S. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904187106 · Cited by 704

Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover

Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670

GLP-1 physiology informs the pharmacotherapy of obesity

Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510

Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease

Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498

The metabolic actions of glucagon revisited

Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409

Distinct but complementary contributions of PPAR isotypes to energy homeostasis

Dubois, V., Eeckhoute, J., Lefèbvre, P., & Staels, B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88894 · Cited by 397

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity

Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383

Role of Mitochondria in Nonalcoholic Fatty Liver Disease

Nassir, F., & Ibdah, J. A. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15058713 · Cited by 369

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.

Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., & Adeli, K. (2009) · Diabetologia · doi:10.1007/s00125-009-1611-5 · Cited by 283

Islet α cells and glucagon--critical regulators of energy homeostasis

Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266

The role of dysregulated glucagon secretion in type 2 diabetes

D'Alessio, D. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01449.x · Cited by 238

OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin

Chen, L., Shu, Y., Liang, X., Chen, E. C., Yee, S. W., Zur, A. A., Li, S., Xu, L., Keshari, K. R., Lin, M. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314939111 · Cited by 238

Glucagon Receptor Signaling and Lipid Metabolism

Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00413 · Cited by 218

Structure of the full-length glucagon class B G-protein-coupled receptor

Zhang, H., Qiao, A., Yang, D., Yang, L., Dai, A., de Graaf, C., Reedtz‐Runge, S., Dharmarajan, V., Zhang, H., Han, G. W., et al. (2017) · Nature · doi:10.1038/nature22363 · Cited by 212

Interrupted Glucagon Signaling Reveals Hepatic α Cell Axis and Role for L-Glutamine in α Cell Proliferation

Dean, E. D., Li, M., Prasad, N., Wisniewski, S., Deylen, A. V., Spaeth, J. M., Maddison, L. A., Botros, A., Sedgeman, L. R., Bozadjieva-Kramer, N., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.05.011 · Cited by 210

Alpha-, Delta- and PP-cells: Are They the Architectural Cornerstones of Islet Structure and Co-ordination?

Brereton, M. F., Vergari, E., Zhang, Q., & Clark, A. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415583535 · Cited by 206

Glucagon Receptor Signaling and Glucagon Resistance

Janah, L., Kjeldsen, S. A. S., Galsgaard, K. D., Winther‐Sørensen, M., Stojanovska, E., Pedersen, J., Knop, F. K., Holst, J. J., & Albrechtsen, N. J. W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133314 · Cited by 221

Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis

Holst, J. J., Wewer Albrechtsen, N. J., Pedersen, J., & Knop, F. K. (2017) · Diabetes · doi:10.2337/db16-0994 · Cited by 187

Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease

Yabut, J. M., & Drucker, D. J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 189

Acetate Revisited: A Key Biomolecule at the Nexus of Metabolism, Epigenetics and Oncogenesis—Part 1: Acetyl-CoA, Acetogenesis and Acyl-CoA Short-Chain Synthetases

Moffett, J. R., Puthillathu, N., Vengilote, R., Jaworski, D. M., & Namboodiri, A. M. A. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.580167 · Cited by 190

Treatment with LY 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Guzman, C. B., Zhang, X. M., Liu, R., Regev, A., Shankar, S., Garhyan, P., Pillai, S. G., Kazda, C., Chalasani, N., & Hardy, T. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12958 · Cited by 172

The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes

Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162

Activation of the Farnesoid X Receptor Induces Hepatic Expression and Secretion of Fibroblast Growth Factor 21

Cyphert, H. A., Ge, X., Kohan, A. B., Salati, L. M., Zhang, Y., & Hillgartner, F. B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.375907 · Cited by 162

Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases

Hædersdal, S., Andersen, A., Knop, F. K., & Vilsbøll, T. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00817-4 · Cited by 168

The Liver–α-Cell Axis and Type 2 Diabetes

Albrechtsen, N. J. W., Pedersen, J., Galsgaard, K. D., Winther‐Sørensen, M., Suppli, M. P., Janah, L., Gromada, J., Vilstrup, H., Knop, F. K., & Holst, J. J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00251 · Cited by 154

High protein intake reduces intrahepatocellular lipid deposition in humans

Bortolotti, M., Kreis, R., Debard, C., Cariou, B., Faeh, D., Chetiveaux, M., Ith, M., Vermathen, P., Stefanoni, N., Lê, K.-A., et al. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.27296 · Cited by 146

Targeting the glucagon receptor family for diabetes and obesity therapy

Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 144

Structure of the glucagon receptor in complex with a glucagon analogue

Zhang, H., Qiao, A., Yang, L., Eps, N. V., Frederiksen, K. S., Yang, D., Dai, A., Cai, X., Zhang, H., Yi, C., et al. (2018) · Nature · doi:10.1038/nature25153 · Cited by 141

Important Hormones Regulating Lipid Metabolism

Zhang, D., Wei, Y., Huang, Q., Chen, Y., Zeng, K., Yang, W., Chen, J., & Chen, J. (2022) · Molecules · doi:10.3390/molecules27207052 · Cited by 151

Dissociating fatty liver and diabetes

Sun, Z., & Lazar, M. A. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.09.005 · Cited by 143

Integrating the inputs that shape pancreatic islet hormone release

Noguchi, G. M., & Huising, M. O. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0148-2 · Cited by 138

Influence of Dietary Macronutrients on Liver Fat Accumulation and Metabolism

Parry, S. A., & Hodson, L. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000524 · Cited by 141

AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients

Kaufman, A., Abuqayyas, L., Denney, W. S., Tillman, E. J., & Rolph, T. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100057 · Cited by 131

Gut-liver interaction in triglyceride-rich lipoprotein metabolism

Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 131

Hepatic transcriptional responses to fasting and feeding

Bideyan, L., Nagari, R., & Tontonoz, P. (2021) · Genes & Development · doi:10.1101/gad.348340.121 · Cited by 126

Update on the molecular biology of dyslipidemias

Ramasamy, I. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.033 · Cited by 131

Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes

Ali, S., & Drucker, D. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90887.2008 · Cited by 124

Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans

Hansen, J. S., Clemmesen, J. O., Secher, N. H., Hoene, M., Drescher, A., Weigert, C., Pedersen, B. K., & Plomgaard, P. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.06.001 · Cited by 123

Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes

Finan, B., Capozzi, M. E., & Campbell, J. E. (2019) · Diabetes · doi:10.2337/dbi19-0004 · Cited by 124

Metabolic Syndrome and Male Fertility

Martins, A. D., Majzoub, A. A., & Agawal, A. (2018) · The World Journal of Men s Health · doi:10.5534/wjmh.180055 · Cited by 119

Glucagon-Induced Acetylation of Foxa2 Regulates Hepatic Lipid Metabolism

von Meyenn, F., Porstmann, T., Gasser, E., Selevsek, N., Schmidt, A., Aebersold, R. H., & Stoffel, M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.014 · Cited by 122

Short‐term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes

Kelly, R. P., Garhyan, P., Raddad, E., Fu, H., Lim, C. N., Prince, M. J., Pinaire, J. A., Loh, M. T., & Deeg, M. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12446 · Cited by 110

Transcriptional and Chromatin Regulation during Fasting – The Genomic Era

Goldstein, I., & Hager, G. L. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.09.005 · Cited by 110

The past, present, and future physiology and pharmacology of glucagon

Capozzi, M. E., D’Alessio, D. A., & Campbell, J. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.001 · Cited by 114

Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance

Savage, D. B., & Semple, R. K. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833b7782 · Cited by 112

Hepatic energy state is regulated by glucagon receptor signaling in mice

Berglund, E. D., Lee, R. S., Lustig, D. G., Lynes, S. E., Donahue, E. P., Camacho, R. C., Meredith, M. E., Magnuson, M. A., Charron, M. J., & Wasserman, D. H. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38650 · Cited by 108

Major Facilitator Superfamily Domain-Containing Protein 2a (MFSD2A) Has Roles in Body Growth, Motor Function, and Lipid Metabolism

Berger, J. H., Charron, M. J., & Silver, D. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050629 · Cited by 105

Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys

Okamoto, H., Kim, J., Aglione, J., Lee, J., Cavino, K., Na, E., Rafique, A., Kim, J. H., Harp, J., Valenzuela, D. M., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1011 · Cited by 100

Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver

Hasenour, C. M., Berglund, E. D., & Wasserman, D. H. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.018 · Cited by 100

Determinants of VLDL-triglycerides production

Nielsen, S., & Karpe, F. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283544956 · Cited by 94

Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21

Kim, T., Nason, S., Holleman, C., Pepin, M., Wilson, L., Berryhill, T. F., Wende, A. R., Steele, C., Young, M. E., Barnes, S., et al. (2018) · Diabetes · doi:10.2337/db17-1502 · Cited by 97

Mechanisms of hepatic fatty acid oxidation and ketogenesis during fasting

Ruppert, P. M. M., & Kersten, S. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.10.002 · Cited by 103

Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy

Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92

Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?

Arafat, A. M., Kaczmarek, P., Skrzypski, M., Pruszyńska‐Oszmałek, E., Kolodziejski, P. A., Szczepankiewicz, D., Sassek, M., Wojciechowicz, T., Wiedenmann, B. J., Pfeiffer, A. F. H., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2803-y · Cited by 90

Glucagon Control on Food Intake and Energy Balance

Al–Massadi, O., Fernø, J., Diéguez, C., Nogueiras, R., & Quiñones, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163905 · Cited by 94

Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes

Scheen, A. J., Paquot, N., & Lefèbvre, P. J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1395020 · Cited by 88

The Liver–α-Cell Axis in Health and in Disease

Richter, M. M., Galsgaard, K. D., Elmelund, E., Knop, F. K., Suppli, M. P., Holst, J. J., Winther‐Sørensen, M., Kjeldsen, S. A. S., & Albrechtsen, N. J. W. (2022) · Diabetes · doi:10.2337/dbi22-0004 · Cited by 87

Insights into the Hexose Liver Metabolism—Glucose versus Fructose

Geidl-Flueck, B., & Gerber, P. (2017) · Nutrients · doi:10.3390/nu9091026 · Cited by 85

Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes

Yang, J., MacDougall, M. L., McDowell, M. T., Xi, L., Wei, R., Zavadoski, W. J., Molloy, M. P., Baker, J. D., Kühn, M., Cabrera, O., et al. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-281 · Cited by 82

Glucagon Stimulates Hepatic FGF21 Secretion through a PKA- and EPAC-Dependent Posttranscriptional Mechanism

Cyphert, H. A., Alonge, K. M., Ippagunta, S. M., & Hillgartner, F. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094996 · Cited by 80

Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice

Sharma, A. X., Quittner-Strom, E. B., Lee, Y., Johnson, J. A., Martin, S. A., Yu, X., Li, J., Lu, J., Cai, Z. P., Chen, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.065 · Cited by 71

5-Aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) Effect on Glucose Production, but Not Energy Metabolism, Is Independent of Hepatic AMPK in Vivo

Hasenour, C. M., Ridley, D. E., Hughey, C. C., James, F. D., Donahue, E. P., Shearer, J., Viollet, B., Foretz, M., & Wasserman, D. H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.528232 · Cited by 76

Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction

Ali, S., Ussher, J. R., Baggio, L. L., Kabir, M. G., Charron, M. J., Ilkayeva, O., Newgard, C. B., & Drucker, D. J. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.005 · Cited by 69

Remodeling of Hepatic Metabolism and Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides

Watanabe, C., Seino, Y., Miyahira, H., Yamamoto, M., Fukami, A., Ozaki, N., Takagishi, Y., Sato, J., Fukuwatari, T., Shibata, K., et al. (2011) · Diabetes · doi:10.2337/db11-0739 · Cited by 70

Lack of glucagon receptor signaling and its implications beyond glucose homeostasis

Charron, M. J., & Vuguin, P. M. (2015) · Journal of Endocrinology · doi:10.1530/joe-14-0614 · Cited by 68

Characterization of major elements of insulin signaling cascade in chicken adipose tissue: Apparent insulin refractoriness

Dupont, J., Métayer, S., Ji, B., Ramé, C., Gespach, C. P., Voy, B. H., & Simon, J. (2012) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2011.12.030 · Cited by 61

Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol

Spolitu, S., Okamoto, H., Dai, W., Zadroga, J. A., Wittchen, E. S., Gromada, J., & Ozcan, L. (2019) · Circulation Research · doi:10.1161/circresaha.118.313648 · Cited by 64

Futile lipid cycling: from biochemistry to physiology

Sharma, A. K., Khandelwal, R., & Wolfrum, C. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01003-0 · Cited by 66

Effects of Acute Hyperglucagonemia on Hepatic and Intestinal Lipoprotein Production and Clearance in Healthy Humans

Xiao, C., Pavlic, M., Szeto, L., Patterson, B. W., & Lewis, G. F. (2010) · Diabetes · doi:10.2337/db10-0763 · Cited by 61

Glucagon's Metabolic Action in Health and Disease

Zeigerer, A., Sekar, R., Kleinert, M., Nason, S. R., Habegger, K. M., & Müller, T. D. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200013 · Cited by 87

Hypoxia via ERK Signaling Inhibits Hepatic PPARα to Promote Fatty Liver

Mooli, R. G. R., Rodriguez, J., Takahashi, S., Solanki, S. A., Gonzalez, F. J., Ramakrishnan, S. K., & Shah, Y. M. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.03.011 · Cited by 59

Hepatic glucagon action: beyond glucose mobilization

Kajani, S., Laker, R. C., Ratkova, E. L., Will, S., & Rhodes, C. J. (2024) · Physiological Reviews · doi:10.1152/physrev.00028.2023 · Cited by 65

Regulator of G Protein Signaling (RGS16) Inhibits Hepatic Fatty Acid Oxidation in a Carbohydrate Response Element-binding Protein (ChREBP)-dependent Manner

Pashkov, V., Huang, J., Parameswara, V., Kędzierski, W., Kurrasch, D. M., Tall, G. G., Esser, V., Gerard, R. D., Uyeda, K., Towle, H. C., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.216234 · Cited by 59

Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use

Taleb, N., Haidar, A., Messier, V., Gingras, V., Legault, L., & RABASA-LHORET, R. P. R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12789 · Cited by 59

Hyperglucagonemia in youth is associated with high plasma free fatty acids, visceral adiposity, and impaired glucose tolerance

Manell, H., Kristinsson, H., Kullberg, J., Ubhayasekera, S. J. K. A., Mörwald, K., Staaf, J., Cadamuro, J., Zsoldos, F., Göpel, S., Sargsyan, E., et al. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12890 · Cited by 57

Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis

Rui, L., & Lin, J. D. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062220-105200 · Cited by 59

Hormone-like fibroblast growth factors and metabolic regulation

Long, Y. C., & Kharitonenkov, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.04.002 · Cited by 55

Energy-sensing Factors Coactivator Peroxisome Proliferator-activated Receptor γ Coactivator 1-α (PGC-1α) and AMP-activated Protein Kinase Control Expression of Inflammatory Mediators in Liver

Buler, M., Aatsinki, S., Skoumal, R., Komka, Z., Tóth, M., Kerkelä, R., Georgiadi, A., Kersten, S., & Hakkola, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.302356 · Cited by 53

Nutrient regulation of glucagon secretion: involvement in metabolism and diabetes

Marroquí, L., Alonso‐Magdalena, P., Merino, B., Fuentes, E., Nadal, Á., & Quesada, I. (2014) · Nutrition Research Reviews · doi:10.1017/s0954422414000031 · Cited by 57

Lipid sensing by PPARα: Role in controlling hepatocyte gene regulatory networks and the metabolic response to fasting

Fougerat, A., Bruse, J., Polizzi, A., Montagner, A., Guillou, H., & Wahli, W. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101303 · Cited by 56

Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status

Hu, C., Chen, Y., Yin, X., Xu, R., Yin, C., Wang, C., & Zhao, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02098-3 · Cited by 69

A Critical Role of Fatty Acid Binding Protein 4 and 5 (FABP4/5) in the Systemic Response to Fasting

Syamsunarno, M. R. A. A., Iso, T., Hanaoka, H., Yamaguchi, A., Obokata, M., Koitabashi, N., Goto, K., Hishiki, T., Nagahata, Y., Matsui, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079386 · Cited by 52

Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor

Zhao, F., Zhang, C., Zhou, Q., Hang, K., Zou, X., Chen, Y., Wu, F., Rao, Q., Dai, A., Yin, W., et al. (2021) · eLife · doi:10.7554/elife.68719 · Cited by 48

Downregulation of the kidney glucagon receptor, essential for renal function and systemic homeostasis, contributes to chronic kidney disease

Wang, M.-Y., Zhang, Z., Zhao, S., Onodera, T., Sun, X.-N., Zhu, Q., Li, C., Li, N., Chen, S., Paredes, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.024 · Cited by 52

CrbpI Modulates Glucose Homeostasis and Pancreas 9-cis-Retinoic Acid Concentrations

Kane, M. A., Folias, A. E., Pingitore, A., Perri, M., Krois, C. R., Ryu, J. Y., Cione, E., & Napoli, J. L. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05516-11 · Cited by 48

NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease

Li, Y., Chen, M., Zhou, Y., Tang, C., Zhang, W., Zhong, Y., Chen, Y., Zhou, H. Y., & Sheng, L. (2020) · Theranostics · doi:10.7150/thno.40149 · Cited by 48

Exercise Intensity Modulation of Hepatic Lipid Metabolism

Lira, F. S., Carnevali, L. C., Zanchi, N. E., dos Santos, R. V. T., Lavoie, J.-M., & Seelaender, M. C. L. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/809576 · Cited by 47

Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models

Vuguin, P. M., & Charron, M. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01447.x · Cited by 47

Glucagon as a Critical Factor in the Pathology of Diabetes

Edgerton, D. S., & Cherrington, A. D. (2011) · Diabetes · doi:10.2337/db10-1594 · Cited by 47

Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling: implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis

Wang, H., Zhao, M., Sud, N., Christian, P., Shen, J., Song, Y., Pashaj, A., Zhang, K., Carr, T. P., & Su, Q. (2016) · Scientific Reports · doi:10.1038/srep32246 · Cited by 53

The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism

Möllmann, J., Kahles, F., Lebherz, C., Kappel, B. A., Baeck, C., Tacke, F., Werner, C., Federici, M., Marx, N., & Lehrke, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12839 · Cited by 48

Lipocalin 13 protein protects against hepatic steatosis by both inhibiting lipogenesis and stimulating fatty acid β-oxidation

Sheng, L., Cho, K. W., Zhou, Y., Shen, H., & Rui, L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.256677 · Cited by 45

Inhibiting or antagonizing glucagon: making progress in diabetes care

Lefèbvre, P. J., Paquot, N., & Scheen, A. J. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12480 · Cited by 45

Cell Metabolism Article The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting

Longuet, C., Sinclair, E. M., Maida, A., Baggio, L. L., Maziarz, M., & Charron, M. J. (2013)

GPR109a Signaling Alters the Hepatic Response to Fasting

Foy, C. E., Hepler, C., & Renquist, B. J. (2016) · The FASEB Journal · doi:10.1096/fasebj.30.1_supplement.850.6

Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression

Nason, S. R., Kim, T., ANTIPENKO, J. P., Finan, B., DiMarchi, R. D., Hunter, C. S., & Habegger, K. M. (2019) · Endocrinology · doi:10.1210/endocr/bqz013 · Cited by 25

Female glucagon receptor knockout mice are prone to steatosis but resistant to weight gain when fed a MASH ‐promoting GAN diet and a high‐fat diet

Galsgaard, K. D., Elmelund, E., Hunt, J. E., Smits, M. M., Grevengoed, T. J., Christoffersen, C., Færgeman, N. J., Havelund, J. F., Albrechtsen, N. J. W., & Holst, J. J. (2025) · Physiological Reports · doi:10.14814/phy2.70235 · Cited by 2

Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice

Galsgaard, K. D., Elmelund, E., Johansen, C. D., Bomholt, A. B., Kizilkaya, H. S., Ceutz, F. R., Hunt, J. E., Kissow, H., Winther‐Sørensen, M., Sørensen, C. M., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101639 · Cited by 19